Medixine Oy

Medixine Oy specializes in medical software platforms designed to integrate with patient monitoring devices. Their products, such as the Medixine Suite 10, Suite 9.0, Suite 11, and Falck AcuCare, are built to collect and analyze real-time health data. These solutions are primarily aimed at improving clinical decision-making for patients with chronic conditions by providing actionable insights to healthcare providers.

Medixine Oy is headquartered in Finland. Since its devices are classified as EU Class IIa medical devices, they must comply with the EU’s Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR), depending on the specific product. This includes adherence to EU-wide requirements for software-as-a-medical-device (SaMD) and integrated diagnostic systems, ensuring their products meet safety, performance, and regulatory standards before being listed in the EU’s eudamed database.

Medixine Oy’s devices are registered in the eudamed database, which is the official EU-wide registry for medical devices. This listing confirms their compliance with EU regulatory requirements, allowing healthcare providers and authorities to verify their authorized status under the Medical Device Regulation (MDR).

Medixine Oy’s devices fall under EU Class IIa, the second-lowest risk classification for medical devices. This classification is determined based on factors like the device’s intended purpose, potential risks to patients, and the level of intervention it involves. Class IIa devices require compliance with stricter regulatory controls than Class I but less than higher-risk classes (e.g., Class IIb or III), ensuring a balance between safety oversight and innovation.